{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-009225","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.269762+00:00","generated_at":"2026-06-26T09:16:15.858724+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncotelic forms joint venture with Dragon Overseas; Dragon to invest $27.6M for 55% stake","bullets":["Dragon Overseas invests $27.6M in cash and assets for 55% of JV; Oncotelic contributes OT-101 licenses for 45%.","Oncotelic eligible for up to $50M from sale of RPD Priority Review Voucher for OT-101 (DIPG) after marketing approval.","JV to develop TGF-β therapeutics, initially focusing on OT-101 for DIPG, pancreatic cancer, and glioblastoma.","If Series A of ≥$20M not completed by Aug 31, 2022, Dragon's funding drops to $250K/month; licenses revert on termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-009225","json":"https://secwatch.observer/filing/0001493152-22-009225.json","markdown":"https://secwatch.observer/filing/0001493152-22-009225.md","text":"https://secwatch.observer/filing/0001493152-22-009225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222009225/0001493152-22-009225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222009225/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T09:16:15.858724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}